267 related articles for article (PubMed ID: 18408581)
1. Case-control comparison of at-home and hospital care for allogeneic hematopoietic stem-cell transplantation: the role of oral nutrition.
Svahn BM; Remberger M; Heijbel M; Martell E; Wikström M; Eriksson B; Milovsavljevic R; Mattsson J; Ringdén O
Transplantation; 2008 Apr; 85(7):1000-7. PubMed ID: 18408581
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation.
Svahn BM; Ringdén O; Remberger M
Bone Marrow Transplant; 2005 Sep; 36(6):511-6. PubMed ID: 16025151
[TBL] [Abstract][Full Text] [Related]
3. Poor oral nutrition after allogeneic stem cell transplantation correlates significantly with severe graft-versus-host disease.
Mattsson J; Westin S; Edlund S; Remberger M
Bone Marrow Transplant; 2006 Nov; 38(9):629-33. PubMed ID: 16964269
[TBL] [Abstract][Full Text] [Related]
4. Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease.
Ringdén O; Remberger M; Holmberg K; Edeskog C; Wikström M; Eriksson B; Finnbogadottir S; Fransson K; Milovsavljevic R; Omazic B; Svenberg P; Mattsson J; Svahn BM
Biol Blood Marrow Transplant; 2013 Feb; 19(2):314-20. PubMed ID: 23089563
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
[TBL] [Abstract][Full Text] [Related]
6. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
[TBL] [Abstract][Full Text] [Related]
7. Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? A pilot trial.
Svahn BM; Bjurman B; Myrbäck KE; Aschan J; Ringdén O
Bone Marrow Transplant; 2000 Nov; 26(10):1057-60. PubMed ID: 11108303
[TBL] [Abstract][Full Text] [Related]
8. Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be more advantageous than isolation in hospital.
Ringdén O; Remberger M; Törlén J; Engström M; Fjaertoft G; Mattsson J; Svahn BM
Pediatr Transplant; 2014 Jun; 18(4):398-404. PubMed ID: 24802347
[TBL] [Abstract][Full Text] [Related]
9. CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Bogunia-Kubik K; Duda D; Suchnicki K; Lange A
Haematologica; 2006 Dec; 91(12):1628-34. PubMed ID: 17145599
[TBL] [Abstract][Full Text] [Related]
10. Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies.
Fernández-Avilés F; Carreras E; Urbano-Ispizua A; Rovira M; Martínez C; Gaya A; Granell M; Ramiro L; Gallego C; Hernando A; Segura S; García L; González M; Valverde M; Montserrat E
J Clin Oncol; 2006 Oct; 24(30):4855-61. PubMed ID: 17001069
[TBL] [Abstract][Full Text] [Related]
11. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
12. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
13. Treatment costs and survival in patients with grades III-IV acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation during three decades.
Svahn BM; Ringdén O; Remberger M
Transplantation; 2006 Jun; 81(11):1600-3. PubMed ID: 16770251
[TBL] [Abstract][Full Text] [Related]
14. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
15. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
Fuji S; Kim SW; Fukuda T; Mori S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Heike Y; Tobinai K; Tanosaki R; Takaue Y
Biol Blood Marrow Transplant; 2008 May; 14(5):510-7. PubMed ID: 18410893
[TBL] [Abstract][Full Text] [Related]
16. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
17. Nutritional support for patients suffering from intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Imataki O; Nakatani S; Hasegawa T; Kondo M; Ichihashi K; Araki M; Ishida T; Kim SW; Mori S; Fukuda T; Tobinai K; Tanosaki R; Makimoto A; Takaue Y
Am J Hematol; 2006 Oct; 81(10):747-52. PubMed ID: 16865687
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation.
Wirk B; Klumpp TR; Ulicny J; Herman JH; Gajewski JL; Martin ME; Emmons RV; Mangan KF
Transfusion; 2008 Jan; 48(1):163-8. PubMed ID: 17900280
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants.
Hoyt R; Ritchie DS; Roberts AW; Macgregor L; Curtis DJ; Szer J; Grigg AP
Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
